

AVITA MEDICAL LIMITED (ASX: AVH) Results of Extraordinary General Meeting

23 July 2018 – In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, details of the resolutions and the proxies received in respect of each resolution are set out in the attached Voting Results summary.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a REGENERATIVE EPITHELIAL SUSPENSION™, an autologous suspension comprised of the patient's skin cells and wound healing factors that are necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

In the United States, the RECELL Device is an investigational device limited by federal law to investigational use. In September 2017, AVITA Medical submitted to the U.S. Food and Drug Administration (FDA) a PreMarket Approval (PMA) application for RECELL Device for the treatment of burn injuries.

In all countries outside of Europe, our portfolio is marketed under the RECELL Device brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL Device is TGA-registered in Australia, and CFDA-cleared in China.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. RECELL Device is designed for the treatment of burns and plastic reconstructive procedures; REGENERCELL™ Autologous Cell Harvesting Device has been formulated for chronic wounds including leg and foot ulcers; and RENOVACELL™ Autologous Cell Harvesting Device is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION:

<p>OUS Media Monsoon Communications Sarah Kemter Phone: +61 (0)3 9620 3333 Mobile: +61 (0)407 162 530 sarahk@monsoon.com.au</p> <p>US Media Syneos Health Public Relations David Polk Phone: +1 (310) 309 1029 Mobile +1 (805) 428 5775 david.polk@syneoshealth.com</p>	<p>Investors: Westwicke Partners Caroline Corner Phone +1 (415) 202-5678 caroline.corner@westwicke.com</p> <p>AVITA Medical Ltd Dale A. Sander Chief Financial Officer Phone +1 (858) 663-6993 dsander@avitamedical.com</p>
---	--

AVITA MEDICAL LIMITED
EXTRAORDINARY GENERAL MEETING
Monday, 23 July 2018
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of prior issue Shares	Ordinary	133,737,890 91.09%	11,364,025 7.74%	1,717,295 1.17%	1,576,766	Item was passed on a show of hands			Carried
2 Approval to issue shares to raise up to \$3.25 mil	Ordinary	112,199,481 83.33%	20,473,666 15.21%	1,970,585 1.46%	13,752,244	Item was passed on a show of hands			Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.